Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer.
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer.
复制标题
DOI：
10.1155/2012/986725
复制
发表时间：
2012
影响因子：
--
通讯作者：
Kato Y
中科院分区：
文献类型：
--
作者：
Baba Y;Fujii M;Tokumaru Y;Kato Y
尽管EGFR在头颈部鳞状细胞癌(HNSCC)中高水平表达，突变极其罕见，但EGFR抑制剂的单一治疗显示出有限的成功。PI3K/Akt通路与细胞存活有关，抑制磷脂酰肌醇(PI)的合成对HNSCC具有抗增殖、抗侵袭和抗血管生成作用。在HNSCC中，通过PI3K/Akt通路观察到EGFR和IGF1R信号之间的分子串扰，在NFκB和STAT3信号通路之间也观察到分子串扰。因此，表皮生长因子受体拮抗剂与同时抑制Akt和NFκB激活的药物联合使用可能会克服肝癌对表皮生长因子受体拮抗剂的耐药性。
Although EGFR is expressed at high levels in head and neck squamous cell carcinomas (HNSCCs) and mutations are extremely rare, monotherapy with EGFR inhibitors has shown limited success. The PI3kinase/Akt pathway is responsible for cellular survival, and inhibition of phosphatidylinositol (PI) synthesis has antiproliferative, anti-invasive, and antiangiogenesis effects on HNSCC. Molecular crosstalk has been observed between EGFR and IGF1R signaling through the PI3kinase/Akt pathway in HNSCC, as has molecular crosstalk between the NFκB and STAT3 signaling pathways. Therefore, the combination of an EGFR antagonist with an agent that inhibits the activation of both Akt and NFκB may overcome resistance to EGFR antagonists in HNSCC.